BamSEC and AlphaSense Join Forces
Learn More

CNS Pharmaceuticals Inc.

NASDAQ: CNSP    
Share price (9/16/25): $9.14    
Market cap (9/16/25): $5.252 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 32 pages Securities Purchase Agreement
12/34/56
EX-10.27
from S-1 34 pages Securities Purchase Agreement
12/34/56
EX-10.27
from DRS 34 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 21 pages Stock Purchase Agreement Between Cns Pharmaceuticals, Inc., and Cortice Biosciences, Inc., Dated: July 29, 2024
12/34/56
EX-10.1
from 8-K 33 pages Exclusive License Agreement for Tpi-287 Between Cortice Biosciences, Inc. and Cns Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 3 pages Waiver and Consent Agreement
12/34/56
EX-10.2
from 8-K 5 pages Confidential Cns Pharmaceuticals, Inc. Attention: Christopher Downs 2100 West Loop South Suite 900 Houston, Tx 77027 the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages June 26, 2024 Confidential the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 35 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 6 pages June 14, 2024 Confidential Cns Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South Suite 900 Houston, Tx 77027 the Purpose of This Financial Advisory Agreement (This “Agreement”) Is to Confirm the Engagement of A.G.P./ALLIANCE Global Partners (“A.G.P.”) by Cns Pharmaceuticals, Inc. (The “Company”) to Render Financial Services (As Defined Below) to the Company
12/34/56
EX-10.1
from 8-K 34 pages Securities Purchase Agreement
12/34/56
EX-10.23
from S-1 36 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 11 pages Cns Pharmaceuticals, Inc. 2020 Equity Plan
12/34/56
EX-10.2
from 8-K 3 pages Amendment to Common Stock Purchase Warrants
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.22
from S-1/A 35 pages Securities Purchase Agreement
12/34/56
EX-10.22
from S-1 34 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 9 pages October 16, 2023 To: Re:inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder
12/34/56